STOCK TITAN

Affimed N.V. - AFMD STOCK NEWS

Welcome to our dedicated page for Affimed N.V. news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed N.V. stock.

Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company headquartered in Mannheim, Germany, with additional offices in New York, NY. Affimed is dedicated to leveraging the power of the innate immune system to develop innovative immuno-oncology therapies primarily aimed at treating various cancers. The company is at the forefront of developing its proprietary innate cell engagers (ICE®), which are designed to target and eliminate both hematologic and solid tumors.

At the core of Affimed's innovation is their ROCK® platform, a state-of-the-art technology that generates customized ICE® molecules. These molecules harness the natural power of immune cells, such as natural killer (NK) cells and T-cells, to target and destroy cancer cells. Affimed's lead products include AFM13 (acimtamig), AFM24, and AFM28, which are currently undergoing various stages of clinical trials.

AFM13, the company's flagship innate cell engager, shows promise in treating CD30-positive hematologic tumors. It has demonstrated significant clinical efficacy in heavily pretreated patients with refractory Hodgkin lymphoma, achieving high objective response rates (ORR) and complete response (CR) rates. AFM13 is being investigated in combination with NK cells in the LuminICE-203 study, with initial data expected in the first half of 2024.

AFM24 is another key candidate, targeting EGFR-expressing solid tumors. It is currently being tested in combination with atezolizumab, a checkpoint inhibitor, in the AFM24-102 Phase 1/2a study. Recent data showed a disease control rate of 73.3% in heavily pretreated patients with EGFR wild-type non-small cell lung cancer (NSCLC), including significant objective responses. The FDA has granted Fast Track designation for this combination therapy, highlighting its potential to meet unmet medical needs.

AFM28 targets CD123-positive acute myeloid leukemia (AML). Preclinical studies have shown that AFM28 can effectively reduce tumor growth and eliminate leukemic blasts and stem cells. The drug is currently in early clinical development, with future plans to test it in combination with allogeneic off-the-shelf NK cells.

Affimed is also committed to strategic collaborations and partnerships to advance its clinical programs. Notable collaborations include those with Artiva Biotherapeutics, The University of Texas MD Anderson Cancer Center, and Roche. These partnerships are aimed at enhancing the efficacy and safety profiles of Affimed's therapies and bringing innovative treatments to patients more quickly.

Despite facing challenges such as restructuring and a reduction in workforce, Affimed remains focused on advancing its clinical pipeline. The company's strong leadership team, extensive experience in biotechnology and pharmaceuticals, and a clear mission to revolutionize cancer treatment underscore its commitment to giving patients back their innate ability to fight cancer.

For more information about Affimed's people, pipeline, and ongoing projects, please visit www.affimed.com.

Rhea-AI Summary

Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD) announces management participation in key investor conferences this November. The Jefferies Virtual London Healthcare Conference is scheduled for November 17-19, with a presentation on November 17 at 12:20 p.m. GMT. Additionally, Affimed will host meetings during the SVB Leerink Oncology 1x1 Day on November 19. A live webcast of the Jefferies presentation will be available on Affimed's website, followed by a 30-day replay. For more information, contact Affimed's investor relations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.01%
Tags
conferences
-
Rhea-AI Summary

Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD) announced it will unveil third quarter 2020 results on November 10, 2020, at 8:30 a.m. ET. A conference call will follow to discuss financial outcomes and corporate updates. The call is accessible via phone and webcast, with U.S. callers dialing +1-646-741-3167, and international callers using +44 (0) 2071 928338. Interested parties can also access the live audio webcast through the company’s website, where a replay will be available for 30 days post-call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences earnings
-
Rhea-AI Summary

Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc. have entered a clinical collaboration to explore the combination of Affimed's innate cell engager AFM24 with NKMax's autologous NK cell product SNK01. This partnership aims to conduct a first-in-human proof-of-concept trial for patients with EGFR-expressing tumors. Preclinical data indicates a synergistic effect between the two companies' therapies. The trial will evaluate the combined efficacy of these products, potentially enhancing treatment options for patients with high mortality rates from solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
Rhea-AI Summary

Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD) announced the presentation of preclinical data at the upcoming SITC Annual Meeting from its collaboration with MD Anderson Cancer Center and Washington University. The oral presentation is titled AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies and will occur on November 11, 2020. AFM13, a bispecific innate cell engager, targets CD30-positive tumor cells and is actively being tested in a registration-directed trial for relapsed/refractory peripheral T-cell lymphoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced the first dosing of a patient in a groundbreaking clinical study that combines cord blood-derived natural killer (cbNK) cells with AFM13. This innovative trial focuses on patients with recurrent or refractory CD30-positive lymphomas. The study aims to evaluate both the safety and efficacy of this first-in-class treatment, utilizing preloaded NK cells to enhance the immune response against tumors. The trial expects to enroll about 30 patients at MD Anderson Cancer Center, marking a significant step in immuno-oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
-
Rhea-AI Summary

AbCheck announced a grant from the Ministry of Industry and Trade of the Czech Republic, valued at up to €1.44 million over the next 3 years. This funding supports the development of a microfluidic system for discovering rare therapeutic antibodies. The innovative technology allows screening millions of droplets containing antibody-expressing cells daily, enhancing the discovery of functional antibodies critical for cancer treatments. The grant will expedite the creation of specialized bioassays, reinforcing AbCheck's commitment to advanced antibody discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
none
Rhea-AI Summary

Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD) announced its presentation at the Jefferies Virtual Cell Therapy Conference on October 6 at 8:00 a.m. Eastern Time. The event's live webcast will be accessible via the “Investors” section on Affimed’s website and will remain available for 30 days post-event. Affimed focuses on innovative immuno-oncology treatments, leveraging its ROCK® platform for tailored therapies aimed at hematologic and solid tumors. The company is currently advancing studies on AFM13 and AFM24.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
conferences
-
Rhea-AI Summary

Heidelberg, Germany, September 2, 2020 – Affimed N.V. (Nasdaq: AFMD) announced its participation in several investor conferences throughout September 2020. These include:

  • Wells Fargo Virtual Healthcare Conference on September 9, 2020, featuring a fireside chat at 8:00 a.m. ET.
  • Citi’s 15th Annual BioPharma Virtual Conference on September 10, 2020.
  • Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 12:40 p.m. ET.
  • Oppenheimer Fall Healthcare Life Sciences Summit on September 21, 2020, at 3:20 p.m. ET.
Webcasts are available on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
conferences
-
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced its Q2 2020 financial results, reporting revenue of €2.9 million, down from €4.0 million in Q2 2019. The company has €92.6 million in cash, projected to support operations into H1 2022. The AFM13 study has activated 54 sites across 10 countries, with interim analysis expected mid-2021. Additionally, AFM24 is advancing in Phase 1/2a trials, and the collaboration with Genentech has achieved a milestone triggering a payment. Despite a net loss of €12.2 million, the management team is optimistic about ongoing projects and future developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.87%
Tags
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) has appointed Dr. Annalisa Jenkins and Mr. Harry Welten to its Supervisory Board, effective from August 4, 2020. Dr. Jenkins brings over 25 years of pharmaceutical experience, having held leadership roles at companies like Merck Serono and Bristol-Myers Squibb, while Mr. Welten offers extensive financial and U.S. market expertise from his roles in various biotech firms. These appointments aim to enhance corporate governance and strengthen the company's strategic positioning in the biotech industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none

FAQ

What is the current stock price of Affimed N.V. (AFMD)?

The current stock price of Affimed N.V. (AFMD) is $1.19 as of December 23, 2024.

What is the market cap of Affimed N.V. (AFMD)?

The market cap of Affimed N.V. (AFMD) is approximately 19.5M.

What does Affimed N.V. specialize in?

Affimed N.V. specializes in developing immuno-oncology therapies that harness the innate immune system to fight cancer.

What is the ROCK® platform?

The ROCK® platform is Affimed's proprietary technology that generates customized innate cell engagers (ICE®) to target and kill cancer cells.

What are Affimed's key clinical candidates?

Affimed's key clinical candidates include AFM13 (acimtamig), AFM24, and AFM28, targeting various hematologic and solid tumors.

What is AFM13 used for?

AFM13 targets CD30-positive hematologic tumors and is showing promising results in treating refractory Hodgkin lymphoma.

What is the significance of AFM24's Fast Track designation?

The Fast Track designation by the FDA for AFM24 in combination with atezolizumab expedites its development and review process to address unmet medical needs in NSCLC patients.

How does AFM28 work?

AFM28 targets CD123-positive AML cells, engaging NK cells to initiate tumor cell killing through antibody-dependent cellular cytotoxicity.

What collaborations does Affimed have?

Affimed collaborates with entities like Artiva Biotherapeutics, The University of Texas MD Anderson Cancer Center, and Roche to enhance the efficacy and development of its therapies.

Where is Affimed N.V. headquartered?

Affimed N.V. is headquartered in Mannheim, Germany, with additional offices in New York, NY.

What are the recent achievements of Affimed?

Recent achievements include positive clinical data from AFM24 and AFM13 studies, FDA Fast Track designation for AFM24, and strategic partnerships to advance its clinical programs.

What is the company's mission?

Affimed's mission is to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system.

Affimed N.V.

Nasdaq:AFMD

AFMD Rankings

AFMD Stock Data

19.51M
15.48M
6.01%
36.99%
6.27%
Biotechnology
Healthcare
Link
United States of America
Mannheim